# Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

> **NCT06929039** · PHASE1 · COMPLETED · sponsor: **Kashiv BioSciences, LLC** · enrollment: 300 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Abatacept
- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT06929039
- **Lead sponsor:** Kashiv BioSciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-04
- **Primary completion:** 2024-10-16
- **Final completion:** 2025-02-25
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929039, "Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06929039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*